

#6

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Mail Stop Box PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Alana G Kriegsman

/Alana G. Kriegsman/

April 20, 2005

Type or print name

Alana G. Kriegsman, Reg. #41,747

Signature

Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Kristof Van Emelen et al.  
Serial No. : 10/507,271 Art Unit: N/A  
I.A. Filing Date : 03/11/2003 Examiner: N/A  
I. A. No. PCT/EP03/02511  
For : AMINOCARBONYL-DERIVATIVES AS NOVEL  
INHIBITORS OF HISTONE DEACETYLASE

Mail Stop: PCT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS  
UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

Dear Sir or Madam:

The Notification of Missing Requirements states that a sequence listing must be furnished within a given time period.

Applicants believe that no sequence listing is required.

Applicants respectfully request that if in fact a sequence listing is required, that the Patent Office please refer Applicant to the specific sequence within the application.

Enclosed is a copy of the Notification to Comply with Requirements for Patent Applications Containing Nucleotide And/or Amino Acid Sequence Disclosures.

No fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD-2025-PCT/AGK.

Respectfully submitted,

/Alana Kriegsman/  
Alana G. Kriegsman, Reg. #41,747  
Attorney for Applicant

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1495  
Dated: April 20, 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

Rec'd PCT/PTO 22 APR 2005

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/507,271	FIRST NAMED APPLICANT Kristof Van Emelen	ATTY. DOCKET NO. PRD 2025-PCT
---	---	----------------------------------

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/EP03/02511
----------------

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

03/11/2003

03/13/2002

Johnson & Johnson  
 One Johnson & Johnson Plaza  
 New Brunswick, NJ 08933-7003

RECEIVED

APR 08 2005

J&amp;J PAT. DKT. SECTION

CONFIRMATION NO. 4912

371 FORMALITIES LETTER



\*OC000000015639072\*

Date Mailed: 04/04/2005

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Rec'd PCT/PTO

22 APR 2003 Page 2 of 2

A copy of this notice **MUST** be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/507,271	PCT/EP03/02511	PRD 2025-PCT

FORM PCT/DO/EO/922 (371 Formalities Notice)